COMP <GO>
ILMN vs ABBV // ALTMAN Z-SCORE & DEBT/EQUITY
Illumina Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ILMN 5
— ABBV 9
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: ILMN
LAST: $290.06 (+0.44%) • MKT CAP: $43.80B
balance-sheet
9.52
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
balance-sheet
5.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ILMN VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ILMN | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 66.10% | 70.20% | -4.10 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.20% | 29.00% | -10.80 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 47.5x | 33.3x | +14.20 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 2.13% | 3.47% | -1.34 | ABBV | /fcf-yield <GO> |
| Operating Margin | 18.60% | 24.60% | -6.00 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 19.60% | 6.90% | +12.70 | ILMN | /net-margins <GO> |
| Revenue Growth (YoY) | -0.70% | 8.60% | -9.30 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 9.52 | 5.33 | +4.19 | ILMN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ILMN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.1 | 65.1 | -8.00 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.16 | 1.15 | +0.01 | ILMN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 47.9x | 113.1x | -65.20 | ILMN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $43.80B | $513.86B | -$470.06B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ILMN REV | ABBV REV | ILMN GROSS % | ABBV GROSS % | ILMN FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.34B | $61.16B | 66.1% | 70.2% | $931.0M | $17.82B |
| FY 2024 | $4.37B | $56.33B | 65.4% | 70.0% | $709.0M | $17.83B |
| FY 2023 | $4.50B | $54.32B | — | — | $275.3M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ILMN // BETA 1.16
ABBV // BETA 1.15